Bayer Healthcare has entered into a five-year collaboration with Bayer Healthcare, with the aim of developing new ophthalmic therapies targeting retinal diseases.
The strategic research alliance has been formed to accelerate the translation of new approaches from the laboratory to the clinic, giving patients several new treatment options for a range of retinal diseases.
Serious back-of-the-eye conditions targeted by the researchers include age-related macular degeneration, diabetic macular edema, geographic atrophy, Stargardt's disease and retinal vein occlusion.
Under the terms of the agreement, researchers at Bayer and Johns Hopkins' Wilmer Eye Institute are to evaluate new targets and disease mechanisms, drug delivery technologies and biomarkers.
Both parties will contribute personnel and infrastructure to the project, while Bayer will have an option for the exclusive use of the collaboration results.
"There is a critical need for new therapies that treat a variety of serious diseases of the eye," said Peter McDonnell, director of the Wilmer Eye Institute and professor of ophthalmology at the Johns Hopkins University School of Medicine.
"Additional research will allow us the opportunity to make significant advances in this area."
Bayer has strong internal research and development capabilities in ophthalmology, aiming to ensure patients suffering from vision impairment and sight-threatening diseases benefit from new therapies.
The firm regularly collaborates with third parties, supporting multiple projects and initiatives worldwide, as well as partnering with a number of organisations to help improve the lives of people living with a visual impairment or blindness.
Johns Hopkins University's Wilmer Eye Institute brings together top-rated ophthalmologists and optometrists, delivering state-of-the-art ophthalmic care at The Johns Hopkins Hospital and eight satellite locations across the State of Maryland.